etoposide IV / Generic mfg. - LARVOL DELTA

Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study. (PubMed, Lancet Haematol) - P2 | "In patients with mostly CD30-expressing peripheral T-cell lymphomas other than non-anaplastic large-cell lymphoma, CHEP-BV (with or without autologous HSCT) followed by brentuximab vedotin consolidation was safe and active."

Journal • P2 data • Bone Marrow Transplantation • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Novel Coronavirus Disease • Oncology • Peripheral T-cell Lymphoma • T Cell Non-Hodgkin Lymphoma • Thrombocytopenia • Transplantation • TNFRSF8

Concurrent thoracic radiotherapy (TRT), platinum/etoposide chemotherapy, and durvalumab immunotherapy in extensive-stage (ES) small cell lung cancer (SCLC): A phase III trial. (ASCO 2026) - P3 | "Patients received 4 courses of carboplatin (AUC 5), etoposide (100 mg/m2 iv day 1-3 or 100 mg/m2 iv day 1 plus 200 mg/m2 po days 2-4) and durvalumab 1500 mg q3w, followed by durvalumab 1500 mg q4w until progression, unacceptable toxicity or patients wished to discontinue. The addition of TRT after the first cycle of chemo-ICI did not improve treatment outcomes in ES SCLC."

Late-breaking abstract • P3 data • Gastrointestinal Disorder • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Serplulimab Combined With Concurrent Chemoradiotherapy Followed by Serplulimabtherapy for LS-SCLC: A Phase 2 Trial (IASLC-WCLC 2026) - P2 | "Eligible patients received 4 cycles of serplulimab administered concurrently with etoposide plus cisplatin/carboplatin and thoracic radiotherapy, followed by serplulimab maintenance therapy until disease progression or for a maximum of 1 year. Conclusions : In this ongoing phase 2 trial, serplulimab combined with cCRT followed by serplulimab maintenance therapy has demonstrated promising antitumor activity and a favorable early survival trend, with acceptable tolerability and manageable safety profile. Longer follow-up is warranted to validate the survival benefits of this regimen."

P2 data • Lung Cancer • Pneumonia • Small Cell Lung Cancer • Solid Tumor

Pathological Response and MRD Dynamics After Neoadjuvant Serplulimab Plus Chemotherapy in Stage IIB-IIIB(N2) LS-SCLC (IASLC-WCLC 2026) - P2 | "Patients received neoadjuvant therapy consisting of 4 cycles of serplulimab at 300 mg combined with etoposide and either cisplatin or carboplatin. MRD clearance after neoadjuvant therapy was associated with pCR, and surgery further facilitated MRD clearance. The early EFS data are promising; nevertheless, long-term follow-up is ongoing to further confirm the survival benefits of this strategy."

Clinical • Lung Cancer • Small Cell Lung Cancer • Solid Tumor

Expression and Prognostic Impact of B7-H3 in Patients With Extensive-Stage Small-Cell Lung Cancer (IASLC-WCLC 2026) - P3 | "Methods : The expression and prognostic impact of B7-H3 was analyzed using tumor samples from patients with ES-SCLC enrolled in the IMpower133 (NCT02763579), and SKYSCRAPER-02 (NCT04256421) studies and who received either carboplatin/etoposide (CE) or atezolizumab plus CE (ACE). B7-H3 expression is not strongly correlated with SCLC transcription factors or canonical surface antigens, suggesting broad expression across disease subsets. B7-H3 expression is also not a prognostic factor for PFS or OS in patients from the IMpower133 and SKYSCRAPER-02 studies."

Clinical • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • CD276 • PD-L1

Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial (ESMO 2026) - No abstract available

Clinical • Late-breaking abstract • P3 data • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

GNL3 SUMOylation is essential for DNA double-strand break repair by homologous recombination. (PubMed, Nat Commun) - "Breast cancer-derived GNL3 variants disrupting its SUMOylation or SUMO-interacting motif fail to interact with the BLM-DNA2 complex. GNL3 depletion sensitizes homologous recombination-proficient breast cancer cells to etoposide and Olaparib treatment, highlighting GNL3 and its SUMOylation as potential therapeutic targets in cancer."

Journal • Breast Cancer • Oncology • Solid Tumor • DNA2 • GNL3 • RAD51 • SENP3 • USP36

Updates on Systemic Treatments for Advanced Pancreatic Neuroendocrine Neoplasm (IASGO 2026) - "Everolimus and sunitinib are established options for progressive disease...Alkylator-based chemotherapy, including streptozotocin/5-FU andcapecitabine/temozolomide, is preferred when substantial tumor shrinkage is required...NETTER-2 established 177Lu-DOTATATE plus octreotide as an important first-line option for newlydiagnosed, SSTR-positive G2/G3 gastroenteropancreatic NETs with a Ki-67 index of 10–55%.Cabozantinib significantly prolonged PFS in previously treated PanNETs in the CABINET trial.Surufatinib is approved in China, while belzutifan is indicated specifically for VHL-associated pNETsnot requiring immediate surgery. For PanNECs, platinum plus etoposide remains the frontline standard, whereas no universallyaccepted salvage regimen exists. Emerging approaches include targeted alpha therapy and DLL3-directed bispecific T-cell engagers, although their roles in PanNENs remain investigational. Futuretreatment will increasingly rely on integrated molecular profiling,..."

Metastases • Endocrine Cancer • Gastrointestinal Neuroendocrine Carcinoma • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Carcinoma • Neuroendocrine Neoplasm • Neuroendocrine Tumor • Solid Tumor • ATRX • DAXX • DLL3 • SSTR • TP53

Long-Term Follow-Up of Busulfan Plus Cyclophosphamide and Etoposide Versus High-Dose Melphalan as Conditioning in Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma (IMS 2026) - " A total of 35 patients with multiple myeloma, enrolled between March 2016 and September 2021, patients aged 47-67 (median 57 years) with multiple myeloma were enrolled to receive bortezomib, thalidomide and dexamethasone (VTD) induction followed by ASCT. Our study showed that BuCyE is an effective and well-tolerated alternative to HDMEL conditioning, with good PFS."

Hematological Malignancies • Multiple Myeloma • Transplantation

Aponermin+Kt-Decp, a Good Bridging Regimen for Relapsed/Refractory Multiple Myeloma with Extramedullary Disease (IMS 2026) - P | "Clinical trial information: NCT05013190 Apo-KT-DECP: Apo 10 mg/kg, days 1 – 3 and 15 – 18; carfilzomib: 27 mg/m ² , days 1 – 2, 8 – 9, 15 – 16; thalidomide: 100 mg, days 1 – 10 and 15 – 24; cisplatin, etoposide, cyclophosphamide, and dexamethasone at protocol-specified doses. Conclusion ： Our study demonstrates that PFS p rolong ed o bviously with less toxicity in RRMM with EMD . ORR of 2 -cycle was 86.2 %, could be a good choice as bridging regimen ."

Hematological Malignancies • Infectious Disease • Leukopenia • Multiple Myeloma • Respiratory Diseases • Thrombocytopenia

COMMODORE: A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation (clinicaltrials.gov) - P3 | N=276 | Completed | Sponsor: Astellas Pharma Inc | Active, not recruiting ➔ Completed | Trial completion date: Mar 2027 ➔ Jul 2026

Trial completion • Trial completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • FLT3

ZG005 in combination with etoposide and cisplatin for the first-line treatment of advanced neuroendocrine carcinoma (ESMO 2025) - P1/2 | "Background Advanced neuroendocrine carcinoma (NEC) has limited therapeutic options, with etoposide/cisplatin (EP) or etoposide/carboplatin (EC) remaining as the first-line standard. Serious adverse events occurred in 20.7% of pts in the ZG005+EP arms, with two cases (immune-mediated enterocolitis and subclinical myocarditis) deemed treatment-related. Conclusions The combination of ZG005 with standard EP based chemotherapy showed a favorable safety profile and encouraging anti-tumor activities in pts with NEC."

Clinical • Combination therapy • Metastases • Endocrine Cancer • Lung Cancer • Neuroendocrine Carcinoma • Oncology • Small Cell Lung Cancer • Solid Tumor • TIGIT

Nilvanstomig (ZG005), an anti–PD-1/TIGIT bispecific antibody, plus etoposide and cisplatin as first-line treatment for advanced neuroendocrine carcinoma (NEC): A randomized, multicenter, phase 1/2 study (ESMO 2026) - No abstract available

Bispecific • Clinical • Metastases • P1/2 data • Endocrine Cancer • Neuroendocrine Carcinoma • Oncology • Solid Tumor • TIGIT

ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine Carcinoma (clinicaltrials.gov) - P3 | N=440 | Not yet recruiting | Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd

New P3 trial • Endocrine Cancer • Neuroendocrine Carcinoma • Oncology • Solid Tumor

DeLLphi-303: First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (clinicaltrials.gov) - P1 | N=184 | Active, not recruiting | Sponsor: Amgen | Trial completion date: Aug 2028 ➔ May 2030 | Trial primary completion date: Aug 2028 ➔ May 2030

Trial completion date • Trial primary completion date • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Phase I Trial of Concurrent Talazoparib and Consolidative Thoracic Radiotherapy for Patients with Extensive-Stage Small Cell Lung Cancer (ASTRO 2024) - "Materials/ Patients with ES-SCLC without disease progression following 4-6 cycles of platinum/etoposide +/- durvalumab were treated with talazoparib for 1 week prior to and then 2 weeks concurrently with CTRT (30Gy over 10 fractions) for a total of 3 weeks. Talazoparib can be administered safely with CTRT and was found to be tolerable. We identified the RP2D of concurrent RT and talazoparib as 1mg once daily for patients with ES-SCLC. Secondary efficacy endpoints and exploratory correlative assessments are ongoing."

Clinical • P1 data • Anemia • Anorexia • Dermatitis • Dermatology • Fatigue • Gastrointestinal Disorder • Immunology • Lung Cancer • Neutropenia • Oncology • Pain • Small Cell Lung Cancer • Solid Tumor • Thrombocytopenia

EXTENTORCH: A randomized, phase III trial of toripalimab versus placebo, in combination with chemotherapy as a first-line therapy for patients with extensive stage small cell lung cancer (ES-SCLC) (ESMO 2023) - P3 | "Methods Patients with histologically or cytologically confirmed ES-SCLC, stratified by gender and baseline ECOG PS (0 vs. 1) were randomized in a 1:1 ratio to receive 240 mg toripalimab or placebo plus etoposide and cisplatin/carboplatin Q3W for 4-6 cycles, followed by single-agent toripalimab or placebo until progressive disease, intolerable toxicity or up to 2-year treatment. Toripalimab plus chemotherapy had a manageable safety profile, with no new safety signals observed. Conclusions The addition of toripalimab to chemotherapy provided significant improvements in PFS and OS for patients with ES-SCLC with an acceptable safety profile."

Clinical • Combination therapy • IO biomarker • Late-breaking abstract • P3 data • Tumor mutational burden • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • TMB

Correlation Between Mobilization Regimen and CD34+ Stem Cell Yield in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Single-Center Retrospective Analysis (SOHO 2026) - "Interventions: Mobilization regimens included cyclophosphamide plus G-CSF (n = 17); cyclophosphamide plus G-CSF with plerixafor rescue for poor mobilization (n = 8); upfront cyclophosphamide/G-CSF/plerixafor (n = 2); cytarabine plus G-CSF (n = 2); etoposide plus G-CSF with or without plerixafor (n = 2); rescue G-CSF plus plerixafor alone (n = 1); and other complex salvage strategies (n = 1). Cyclophosphamide plus G-CSF with ondemand plerixafor rescue achieved a 100% minimum-yield success rate. Greater lenalidomide exposure was associated with reduced CD34+ yield, supporting earlier mobilization in heavily pretreated patients. Prospective validation in larger cohorts is warranted."

Retrospective data • Hematological Malignancies • Multiple Myeloma • Oncology • CD34

Clinicopathological of Primary Mediastinal Germ Cell Tumors: Five Year Experience at National Respiratory Center in Indonesia (IASLC-WCLC 2026) - "Most patients received bleomisin-etoposide-cisplatin chemotherapy (86%), while teratoma mostly underwent surgical resection (91%). Early recognition of oncologic emergencies is crucial and should be managed promptly. Our study provides the largest single-center experiences of PMGCTs in Indonesia and highlights the need for further multicenter studies to better characterize this rare disease."

Clinical • Germ Cell Tumors • Oncology • Rare Diseases • Respiratory Diseases • Testicular Cancer

Benmelstobart with Anlotinib plus Chemotherapy as First-line Therapy for ES-SCLC: A Randomized, Double-blind, Phase III Trial (IASLC-WCLC 2023) - "Patients were randomly assigned in a 1:1:1 ratio to receive 4 cycles (21-day cycle) of benmelstobart, anlotinib or placebo in the basis of etoposide/carboplatin (EC) (Chemotherapy remains the standard-of-care when study protocol was approved by Center for Drug Evaluation in China as well as PD-(L)1 inhibitor not received the approval), followed by benmelstobart plus anlotinib, anlotinib, or placebo as maintenance therapy until disease progression or toxicity intolerance. Benmelstobart plus anlotinib and chemotherapy reached historically longest OS in ES-SCLC, with an exceed 7.4-month survival extension over chemotherapy. The PFS of this regimen also exceeded 6 months for the first time. The safety profile is tolerable and manageable."

Clinical • P3 data • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor

DeLLphi-312: A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) (clinicaltrials.gov) - P3 | N=350 | Active, not recruiting | Sponsor: Amgen | Recruiting ➔ Active, not recruiting

Enrollment closed • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study. (PubMed, Lancet Haematol) - P1/2 | "Our data suggest that dose-dense BV-ICE is a rapidly administered and active salvage regimen for patients with relapsed or refractory classical Hodgkin lymphoma despite a complete response in this trial lower than the prespecified phase 2 target. Although cross-trial comparisons should be made with caution, activity results seem to be similar to previously presented brentuximab vedotin chemotherapy salvage combinations delivered over much longer durations and can be considered in young (<60 years), transplantation-eligible patients for second-line therapy."

Clinical • Journal • P1/2 data • Bone Marrow Transplantation • Cardiovascular • Diabetes • Febrile Neutropenia • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Neutropenia • Oncology • Pulmonary Embolism • Respiratory Diseases • Septic Shock • Thrombocytopenia • Transplantation

Moderate Incidence but Striking Correlation with TBI of Secondary Malignancies after HSCT in Children with ALL: Long-Term Follow-up from the Prospective International BFM- and Forum-Trials (ASH 2023) - "Only pts with contraindications for TBI received chemo-conditioning, which consisted of i.v. busulfan, cyclophosphamide and etoposide. In the FORUM trial pts >4y of age were randomized to receive either TBI- or chemo-based conditioning regimens; pts 2 y of age at HSCT (94%, n=2024). TBI-based conditioning was applied in 64% (n=1429), while 34% (n=722) of pts received chemo-conditioning."

Clinical • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Basal Cell Carcinoma • Bone Marrow Transplantation • Brain Cancer • Breast Cancer • Chronic Graft versus Host Disease • CNS Tumor • Endocrine Cancer • Glioblastoma • Graft versus Host Disease • Hematological Malignancies • Leukemia • Non-melanoma Skin Cancer • Oncology • Pediatrics • Solid Tumor • Squamous Cell Carcinoma • Thyroid Gland Carcinoma • Transplantation • TP53

A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-nave Extensive-Stage Small Cell Lung Cancer (clinicaltrials.gov) - P3 | N=556 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.

New P3 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

NET-02: A multicenter, randomized, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC). (ASCO 2022) - "A recognised first-line (1L) treatment for advanced disease is etoposide/platinum-based chemotherapy; there is no standard second-line (2L) treatment (area of unmet need). nal-IRI/5-FU, but not docetaxel, met the primary endpoint (exceeding the threshold for efficacy), with manageable toxicity, and warrants evaluation in a phase III trial."

Clinical • P2 data • Endocrine Cancer • Gastrointestinal Disorder • Neuroendocrine Tumor • Oncology • Solid Tumor